Gynecologic Oncology Reports最新文献

{"title":"Concordance of intraoperative cytology with frozen section and final pathology for ovarian neoplasms","authors":"Jacqueline Early ,&nbsp;Gagandeep Kaur ,&nbsp;Lisa Arrigo ,&nbsp;Skylar Gill ,&nbsp;Mary Chacho ,&nbsp;Paul Fiedler ,&nbsp;Linus Chuang","doi":"10.1016/j.gore.2025.101757","DOIUrl":"10.1016/j.gore.2025.101757","url":null,"abstract":"<div><h3>Introduction</h3><div>Intraoperative frozen section analysis (IOFS) is a widely used method for evaluating ovarian masses and guiding surgical decisions. However, IOFS is not always accessible in low-resource settings. Recent research suggests that intraoperative cytology (IOC) may offer a quicker, less equipment-dependent alternative. This study aims to compare IOC and IOFS in women with ovarian neoplasms. The pathologists interpreting IOC were blinded to IOFS findings.</div></div><div><h3>Methods</h3><div>The study included 15 women aged 18 or older undergoing surgery for ovarian mass removal. Patients with biopsy-confirmed malignancies or known recurrences were excluded. After tumor removal, both IOFS and IOC were performed. IOFS involved using a Cryostat for sectioning and H&amp;E staining. IOC used touch/imprint, scrape, and crush techniques. Independent pathologists analyzed the smears, and paraffin-embedded tissue histopathology was the diagnostic gold standard.</div></div><div><h3>Results</h3><div>IOC results were consistent with final pathology in 10 of 15 cases, while IOFS matched in 12 cases. IOC had 4 indeterminate and 1 borderline diagnosis, compared to 1 indeterminate, 1 benign, and 1 borderline diagnosis with IOFS. Three discrepancies between IOC and IOFS were identified, with IOC providing indeterminate results where IOFS ranged from benign to malignant. Indeterminate cases led to malignancy management strategies, including intraoperative staging.</div></div><div><h3>Conclusion</h3><div>This pilot study indicates that intraoperative cytology is a practical and effective method for rapid ovarian neoplasm evaluation. Further research with larger cohorts is needed to assess its comparative performance with frozen section analysis and optimize its methodology. IOC may offer a viable option for intraoperative surgical guidance.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101757"},"PeriodicalIF":1.2,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bricker ileal conduit diversion with ICG technique in 10 steps","authors":"Clara Dujardin ,&nbsp;Fabrice Narducci ,&nbsp;Delphine Hudry ,&nbsp;Arnaud Villers ,&nbsp;Gautier Marcq ,&nbsp;Carlos Martinez Gomez","doi":"10.1016/j.gore.2025.101753","DOIUrl":"10.1016/j.gore.2025.101753","url":null,"abstract":"<div><div>The Bricker ileal conduit is a widely used incontinent urinary diversion, commonly performed after pelvic exenteration. Described by Bricker in 1950 (<span><span>Bricker, 1950</span></span>), it remains popular due to low complication rates and surgical simplicity (<span><span>Martínez-Gómez et al., 2021</span></span>). Early postoperative complications include intestinal or urinary fistulas, while late ones involve ureteral stenosis (<span><span>Hétet et al., 2005</span></span>).</div><div>In women’s cancers, pelvic exenteration often follows radiotherapy or retroperitoneal dissection during aortic lymphadenectomy, involving extensive left-sided ureteral dissection, which complicates ureteral vascularization.</div><div>ICG (indocyanine green) is a safe, widely used technique in oncologic surgery to assess tissue vascularization, reducing fistula and stenosis risks in ileoureteral and ileoileal anastomoses.</div><div>The urinary conduit is made from a 20 cm ileal segment, with ureters anastomosed separately to the proximal end. ICG is injected intravenously to assess ureteral and anastomotic vascularization. The distal end forms a cutaneous stoma.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101753"},"PeriodicalIF":1.2,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143887472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Four years of remission with fulvestrant monotherapy in advanced endometrioid adenocarcinoma of the endometrium Harboring an ESR1 Mutation: A case Report”","authors":"João Felipe Feldmann ,&nbsp;Karoline Duarte ,&nbsp;João Henrique Feldmann ,&nbsp;Mariana Carvalho Gouveia ,&nbsp;Romulo Loss Mattedi ,&nbsp;Fabio Payao Pereira ,&nbsp;Mariana Scaranti","doi":"10.1016/j.gore.2025.101752","DOIUrl":"10.1016/j.gore.2025.101752","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101752"},"PeriodicalIF":1.2,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus in Bangladesh: Challenges and opportunities for prevention","authors":"Md. Salauddin ,&nbsp;Farhana Irin ,&nbsp;Parsairin Disha ,&nbsp;Nashid Sultana Ishi ,&nbsp;Sharmin Akter ,&nbsp;Rifat Ara ,&nbsp;Muzahed Uddin Ahmed ,&nbsp;Md.Golzar Hossain","doi":"10.1016/j.gore.2025.101747","DOIUrl":"10.1016/j.gore.2025.101747","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101747"},"PeriodicalIF":1.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute limb ischemia due to a common iliac artery thrombosis following total pelvic exenteration with pelvic sidewall resection: A case report","authors":"Maria Selloua ,&nbsp;Mathilde Del ,&nbsp;Jean Ségal ,&nbsp;Charlotte Chollet ,&nbsp;Alejandra Martinez","doi":"10.1016/j.gore.2025.101750","DOIUrl":"10.1016/j.gore.2025.101750","url":null,"abstract":"<div><div>Acute limb ischemia following pelvic exenteration with laterally extended endopelvic resection is a rare yet severe complication. Prompt diagnosis is essential for optimal treatment and recovery. This condition should be suspected if the patient presents with rest pain, paresthesia, motor deficit or and sensory loss.</div><div>We report a case of a patient, diagnosed with an acute right limb ischemia at day one following a pelvic exenteration with right pelvic sidewall resection for a recurrent cervical cancer after radiotherapy. Through the collaboration of a multidisciplinary team, the patient was successfully treated with surgical thrombectomy.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101750"},"PeriodicalIF":1.2,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaginal radical hysterectomy in early stage cervical cancer","authors":"E. Bravo,&nbsp;J. Cartagena,&nbsp;C. Urbina,&nbsp;L. Galdames,&nbsp;I. Bravo,&nbsp;F. Núñez,&nbsp;A. Lehuede,&nbsp;A. Jara,&nbsp;C. Alonso,&nbsp;M. Pulgar","doi":"10.1016/j.gore.2025.101744","DOIUrl":"10.1016/j.gore.2025.101744","url":null,"abstract":"<div><h3>Objectives</h3><div>The goal is to communicate the perioperative and oncological results of a single surgical team after Assisted Vaginal Radical Hysterectomy (a-VRH) for early-stage cervical cancer. We also compared these results with a control group of patients who underwent Abdominal Radical Hysterectomy (ARH) during the same period at the same center.</div></div><div><h3>Methods</h3><div>From April 2008 to November 2018, patients with early-stage cervical cancer (FIGO 1A2, 1B1, 1B2 and 2A1) were prospectively recruited to undergo surgical intervention through Radical Hysterectomy Assisted by Videolaparoscopy with Laparoscopic Systematic Pelvic Lymphadenectomy at Gustavo Fricke Hospital in Viña del Mar, Chile. This group of patients has been registered and followed up to date, analyzing epidemiological, surgical, pathological factors, and survival. We present perioperative and oncological results, along with a comparison to a similar consecutive series of 97 patients undergoing Radical Abdominal Hysterectomy (ARH) during the same period at the same center.</div></div><div><h3>Results</h3><div>Overall survival and disease-free survival in a-VRH are not inferior to those in ARH. Complications were observed in a greater proportion in ARH (16.4 % vs. 22.7 %). The hospital stay was 3.6 days for a-VRH and 6 days for ARH. Fewer transfusions were administered in the a-VRH group.</div></div><div><h3>Conclusion</h3><div>We believe that assisted a-VRH is a very good alternative for the surgical treatment of early-stage cervical cancer, as in this series of patients, the cancer outcomes are at least similar to those of ARH, allowing for the benefits of minimally invasive surgery.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101744"},"PeriodicalIF":1.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unconventional success: Achieving long-term remission with pembrolizumab in recurrent high-grade endometrial carcinosarcoma","authors":"Anaiya G. Singh ,&nbsp;Viraj S. Panchal ,&nbsp;Suvarna Guvvala ,&nbsp;Richard P. Mansour","doi":"10.1016/j.gore.2025.101748","DOIUrl":"10.1016/j.gore.2025.101748","url":null,"abstract":"","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101748"},"PeriodicalIF":1.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of telephone reminders on posttreatment follow-up among women treated for cervical precancers in Cameroon: A randomized controlled trial","authors":"Joseph F. Nkfusai ,&nbsp;Simon M. Manga ,&nbsp;Kathleen Nulah ,&nbsp;Calvin Ngalla ,&nbsp;Claude Ngwayu ,&nbsp;Charlotte B. Mbuwir ,&nbsp;Nicholas Tendongfor ,&nbsp;Edie Gregory Halle Ekane ,&nbsp;Joël Fokom Domgue","doi":"10.1016/j.gore.2025.101745","DOIUrl":"10.1016/j.gore.2025.101745","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Effective management of cervical precancerous lesions requires appropriate posttreatment follow-up. In Cameroon like in many Low-and-Middle-Income Countries (LMICs), most women treated for cervical precancers do not present for posttreatment follow-up. The aim of this study was to investigate if a telephone reminder sent to women about missed follow-up appointment could reduce the proportion of those who fail to attend the recommended follow-up, and to examine the association of telephone reminders with posttreatment follow-up adherence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We carried out a randomized controlled trial nested within a cohort of women screened and treated for cervical precancer (based on positive VIA/VILI results) in a screen-and-treat cervical cancer prevention program in Cameroon. Women who had met clinical criteria for posttreatment follow-up of cervical precancer and did not attend the follow-up appointment within 3 years of precancer treatment were randomly selected and allocated in a 1:1 ratio to the intervention group (receiving a telephone call and text message reminder in addition to the counselling done at the clinic after precancer treatment) and the control group (no telephone reminder after the in-clinic counselling following precancer treatment, per standard of care). Women in the intervention group were contacted by phone, reminded on the importance of posttreatment follow-up they had missed, and invited to return to the clinic for follow-up. The telephone calls were followed by a text message to enhance the understanding of the telephone conversation. The rate of posttreatment follow-up in the intervention group was compared to that of the control group six months after the telephone reminders. A logistic regression analysis was carried out to examine the association between telephone reminders and posttreatment follow-up adherence. Statistical significance was set at p &lt; 0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Between 2022 and 2023, up to 203 women treated for cervical precancers who failed to return to the hospital for posttreatment follow-up within 3 years of receiving precancer treatment were enrolled in this study. Posttreatment follow-up following the telephone reminders was 25.6 % (22/86) and 6.1 % (6/99) in the intervention and control groups, respectively (p&lt;0.001). In the logistic regression analysis, women who received the telephone reminders were four times [aOR = 3.97, 95 %CI (1.29––12.17), p=0.016)] more likely to return for precancer posttreatment follow-up compared to those who did not receive the telephone reminders. Women treated for low-grade cervical precancerous lesions were over five times [aOR=5.44, 95%CI (1.00   29.63), p = 0.059] more likely to attend posttreatment follow-up compared to those treated for high-grade lesions. HIV status was not associated with adherence to posttreatment follow-up. The overall posttreatment follow-up rate increased signific","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101745"},"PeriodicalIF":1.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare leptomeningeal recurrence of mucinous ovarian carcinoma","authors":"Gabrielle LeBlanc ,&nbsp;Sarah G. Bell ,&nbsp;William Delfyett ,&nbsp;Brian Enloe ,&nbsp;Madeleine Courtney-Brooks ,&nbsp;Michelle Boisen","doi":"10.1016/j.gore.2025.101749","DOIUrl":"10.1016/j.gore.2025.101749","url":null,"abstract":"<div><div>Ovarian cancer is the fifth most common cause of cancer death in women and represents the deadliest of the gynecologic cancers. Despite treatment, 80 % of patients diagnosed with ovarian cancer will experience recurrence of disease within 18 months. Mucinous ovarian carcinoma represents an exceptionally rare subtype of ovarian cancer, comprising only 1–3 % of cases. Roughly 65–80 % of cases are diagnosed early at FIGO stage I with an excellent prognosis. However, for those diagnosed with advanced stage III-IV primary or recurrent disease, prognosis is extremely poor secondary to aggressive tumor biology and poor response to traditional platinum-based chemotherapy. Ovarian cancer recurrence most commonly arises secondary to transperitoneal and lymphatic spread of neoplastic cells. Central nervous system seeding, particularly leptomeningeal metastasis, is exceptionally rare with only palliative treatment options. Here, we describe a 44-year-old female with leptomeningeal recurrence remote from surgical treatment of stage IA mucinous ovarian carcinoma.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101749"},"PeriodicalIF":1.2,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint Inhibitor-Induced Autoimmune hemolytic anemia in endometrial cancer","authors":"Michael Danziger ,&nbsp;Isabella Hermantin ,&nbsp;Fidela Valea ,&nbsp;Joan Tymon-Rosario","doi":"10.1016/j.gore.2025.101746","DOIUrl":"10.1016/j.gore.2025.101746","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICIs) have transformed management of advanced and recurrent endometrial carcinoma (EC). However, as their use increases, so too does the incidence of rare side effects related to their use. Here we describe a patient with stage IVB serous endometrial carcinoma who developed autoimmune hemolytic anemia (AIHA) following her second neoadjuvant cycle of carboplatin, paclitaxel, and dostarlimab. She was hospitalized, requiring multiple blood transfusions, a prolonged steroid course, and rituximab before stabilization of her anemia. Further cycles of chemotherapy without dostarlimab demonstrated good clinical response and did not reproduce AIHA. This case highlights the emerging multidisciplinary challenges that arise with the use of these novel targeted therapies. As the importance of these therapies increases in gynecologic oncologic management, it will be critical for providers to be able to diagnosis and manage their unique side effects.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101746"},"PeriodicalIF":1.2,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}